NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Selon la bourse, le symbole de l’action peut varier. Par exemple, à la bourse Boerse Stuttgart, les actions de Neurometrix sont négociées sous le symbole NLZD.STU.
Combien d’employés compte Neurometrix ?▼
Au septembre 04, 2026, l'entreprise compte 13 employés.
Dans quel secteur se situe Neurometrix ?▼
Neurometrix opère dans le secteur Santé & Bien-être.
Quand Neurometrix a-t-elle effectué un split d’actions ?▼
La dernière division d’actions de Neurometrix a eu lieu le novembre 20, 2019 avec un ratio de 1:10.
Où se trouve le siège de Neurometrix ?▼
Le siège de Neurometrix est situé à Woburn, États-Unis.